<DOC>
	<DOCNO>NCT02167711</DOCNO>
	<brief_summary>The current standard treatment inoperable intrahepatic cholangiocarcinoma ( bile duct cancer liver ) chemotherapy , limited efficacy . The use selective internal radiotherapy treatment ( SIRT-Y90 ) proven efficacious patient intra-heptic tumor . Previous experience SIRT safe patient intrahepatic cholangiocarcinoma . This study aim study benefit sequential administration SIRT follow standard chemotherapy treatment inoperable intrahepatic cholangiocarcinoma .</brief_summary>
	<brief_title>Treatment Bile Duct Cancer Liver</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Age &gt; 18 year Histological cytological diagnosis cholangiocarcinoma Disease amenable surgery Predominant disease load liver ( case extrahepatic involvement , patient lymph nodes metastasis allow ) Naïve locoregional systemic treatment ( patient develop recurrent disease surgery suitable ) ECOG PS 01 At least one measurable disease lesion accord RECIST v 1.1 Life expectancy 12 week longer Adequate hematological , renal hepatic function Platelet ≥100 x 109 ANC ≥ 1.5 x 109 Bilirubin ≤ 30µmol/L Albumin ≥ 30g/L ALT ≤ 3 ULN INR ≤ 1.5 Serum creatinine ≤ 1.5 x ULN Prior malignancy except cervical carcinomainsitu treat basal cell carcinoma . Any cancer treat curatively &gt; 5 year prior study entry permit . Patients extrahepatic disease regional lymph node metastasis . Evidence ascites cirrhosis , determine clinical radiologic assessment Biliary obstruction possibility drainage Nonmalignant disease would render patient unsuitable treatment accord protocol Prior treatment chemotherapy cholangiocarcinoma Prior radiation therapy upper abdomen Complete thrombosis main portal vein Tumor volume &gt; 50 % normal liver volume Allergy nonionic contrast agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>